InMed Pharmaceuticals Inc

NASDAQ:INMUnited States

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that is engaged in the development, manufacturing and commercialization of rare cannabinoids. It is developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with unmet medical needs (Product Candidates). The Company’s segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceuticals products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides both neuroprotection and reduces intraocular pressure in the eye.

Contact Information

Headquarters

SUITE 310, 815 W. HASTINGS STREETVANCOUVER, BC, Canada V6C 1B4

Phone

604-669-7207

Fax

778-945-6800

Executives

Independent Chairman of the Board

William Garner

President, Chief Executive Officer, Director

Eric Adams

Interim Chief Financial Officer

Jonathan Tegge

Chief Operating Officer

Michael Woudenberg

Senior Vice President - Clinical and Regulatory Affairs

Alexandra Mancini